These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29948743)

  • 21. Pharmacovigilance Programme of India: Recent developments and future perspectives.
    Kalaiselvan V; Thota P; Singh GN
    Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance in oncology.
    Baldo P; Fornasier G; Ciolfi L; Sartor I; Francescon S
    Int J Clin Pharm; 2018 Aug; 40(4):832-841. PubMed ID: 30069667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety signal detection: the relevance of literature review.
    Pontes H; Clément M; Rollason V
    Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fifty years of pharmacovigilance - Medicines safety and public health.
    Laporte JR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):725-32. PubMed ID: 26799344
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A plea for a more epidemiological and patient-oriented pharmacovigilance.
    Scurti V; Romero M; Tognoni G
    Eur J Clin Pharmacol; 2012 Jan; 68(1):11-9. PubMed ID: 21773732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fifteen years of patient reporting -what have we learned and where are we heading to?
    van Hunsel F; Härmark L; Rolfes L
    Expert Opin Drug Saf; 2019 Jun; 18(6):477-484. PubMed ID: 31030578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacovigilance in Germany : It is about time].
    Douros A; Schaefer C; Kreutz R; Garbe E
    Internist (Berl); 2016 Jun; 57(6):616-23. PubMed ID: 27224991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Historical Perspective of Nephrotoxicity.
    Rankin GO; Valentovic MA
    Toxicol Sci; 2018 Aug; 164(2):377-378. PubMed ID: 30053230
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.